IKZF1 Alteration in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Center Report on the Frequency of IKZF1 Deletions and Its Subtypes
Archives of Advances in Biosciences,
Vol. 13 No. 1 (2022),
1 January 2022
,
Page 1-9
https://doi.org/10.22037/aab.v13i2.39286
Abstract
Introduction: The most prevalent malignancy during childhood is B-cell acute lymphoblastic leukemia (B-ALL). Many genetic variations are the causes of B-ALL. IKZF1 alterations are prevalent in childhood B-ALL cases, which are associated with a poor prognosis. This study examined seventy-two pediatric B-ALL patients for the frequency of IKZF1 alteration and types of IKZF1 deletions.
Materials and Methods: In this study, bone marrow aspirate specimens at the stage of diagnosis in pediatric B–ALL patients were used. The diagnosis of B-ALL was performed following cytomorphology, cytochemistry, and immunophenotyping based on the 2016 World Health Organization (WHO) guidelines. ALL translocations, including TCF3-PBX1 fusion, ETV6-RUNX1 fusion, BCR-ABL1 fusion, and KMT2A-AFF1 fusion, were performed on DNA specimens of all patients. IKZF1 status was checked with the SALSA MLPA P335 ALL-IKZF1 probemix Kit.
Results: The common-B ALL subtype was detected in 64/72 patients (88.9%). CD2 and CD13 aberrant expressions were found in 5/72 (6.9%) and 7/72 patients (9.7%), respectively. Molecular analysis for translocation revealed the frequency of ETV6-RUNX1 in 12/72 patients (16.7%) and BCR-ABL1 in 3/72 (4.2%). IKZF1 alterations were found in 13/72 patients (18%), of whom 10 (13.9%) had IKZF1 deletions. Three common types of IKZF1 deletions were found.
Conclusion: The frequency of IKZF1 deletion in this study is similar to the results already obtained in larger studies. The type of IKZF1 deletion related to poor outcomes has a higher frequency in this study. Because of the relatively high prevalence of IKZF1 deletion, its determination is important for better risk stratification and prognosis in pediatric B-ALL patients.
- Acute leukemia, B-ALL, Deletion, IKZF1.
How to Cite
References
Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017; 18(6):719-731. [DOI: 10.1016/S1470-2045(17)30186-9] [PMID] [PMCID]
Roberts KG, Reshmi SC, Harvey RC, Chen IM, Patel K, Stonerock E, et al. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group. Blood. 2018; 132(8):815-24. [DOI: 10.1182/blood-2018-04-841676] [PMID] [PMCID]
Pui CH, Yang JJ, Bhakta N, Rodriguez-Galindo C. Global efforts toward the cure of childhood acute lymphoblastic leukaemia. Lancet Child Adolesc Health. 2018; 2(6):440-54. [DOI: 10.1016/S2352-4642(18)30066-X] [PMID] [PMCID]
Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. Vol. 2012, Hematology / the Education Program of the American Society of Hematology. Hematology Am Soc Hematol Educ Program. 2012; 2012:389-96. [DOI: 10.1182/asheducation-2012.1.389] [PMID]
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360(5):470–80. [DOI: 10.1056/NEJMoa0808253] [PMID] [PMCID]
Vairy S, Tran TH. IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly. Blood Rev. 2020; 44:100677. [DOI: 10.1016/j.blre.2020.100677] [PMID]
Crepinsek K, Marinsek G, Kavcic M, Prelog T, Kitanovski L, Jazbec J, et al. Clinical impacts of copy number variations in B-cell differentiation and cell cycle control genes in pediatric B-cell acute lymphoblastic leukemia: a single centre experience. Radiol Oncol. 2021; 56(1):92-101. [DOI: 10.2478/raon-2021-0050] [PMID] [PMCID]
Yoshida T, Georgopoulos K. Ikaros fingers on lymphocyte differentiation. Int J Hematol. 2014; 100(3):220–9. [DOI: 10.1007/s12185-014-1644-5] [PMID] [PMCID]
Dörge P, Meissner B, Zimmermann M, Möricke A, Schrauder A, Bouquin JP, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2013; 98(3):428-32. [DOI: 10.3324/haematol.2011.056135] [PMID] [PMCID]
Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, et al. IKZF1 plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Oncol. 2018; 36(12):1240–9. [DOI: 10.1200/JCO.2017.74.3617] [PMID]
Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, et al. Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study. Leukemia. 2016; 30(1):32-8. [DOI: 10.1038/leu.2015.199] [PMID]
Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008; 453(7191):110-4. [DOI: 10.1038/nature06866] [PMID]
Dupuis A, Gaub MP, Legrain M, Drenou B, Mauvieux L, Lutz P, et al. Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia. 2013; 27(2):503-7. [DOI: 10.1038/leu.2012.204] [PMID]
Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell’Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009; 114(10):2159-67. [DOI: 10.1182/blood-2008-08-173963] [PMID]
Kastner P, Dupuis A, Gaub MP, Herbrecht R, Lutz P, Chan S. Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res. 2013; 3(1):1-13. [PMID] [PMCID]
Rogers JH, Gupta R, Reyes JM, Gundry MC, Medrano G, Guzman A, et al. Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities. Blood Adv. 2021; 5(19):3876-90. [DOI: 10.1182/bloodadvances.2020002408] [PMID] [PMCID]
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. [DOI: 10.1182/blood-2016-03-643544] [PMID]
Supriyadi E, Veerman AJP, Sutaryo, Purwanto I, vd Ven PM, Cloos J. Myeloid antigen expression in childhood acute lymphoblastic leukemia and its relevance for clinical outcome in indonesian ALL-2006 protocol. J Oncol. 2012; 2012:1-7. [DOI: 10.1155/2012/135186] [PMID] [PMCID]
Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood. 2012; 120(6):1165-74. [DOI: 10.1182/blood-2012-05-378943] [PMID] [PMCID]
Hamadeh L, Enshaei A, Schwab C, Alonso CN, Attarbaschi A, Barbany G, et al. Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Adv. 2019; 3(2):148-57. [DOI: 10.1182/bloodadvances.2018025718] [PMID] [PMCID]
Moorman AV, Enshaei A, Schwab C, Wade R, Chilton L, Elliott A, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood. 2014; 124(9):1434–44. [DOI: 10.1182/blood-2014-03-562918] [PMID]
Moreno Lorenzana D, Juárez Velázquez M del R, Reyes León A, Martínez Anaya D, Hernández Monterde A, Salas Labadía C, et al. CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways. J Pathol Clin Res. 2021; 7(4):410-21. [DOI: 10.1002/cjp2.211] [PMID] [PMCID]
Cui L, Gao C, Wang CJ, Zhao XX, Li WJ, Li ZG, et al. Combined analysis of IKZF1 deletions and CRLF2 expression on prognostic impact in pediatric B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2021; 62(2):410-18.[DOI: 10.1080/10428194.2020.1832668] [PMID]
Vshyukova VS, Krasko OV, Yanchanka DA, Meleshko AN. Aberrant IKZF1 gene as relapse predictor in standard-risk pediatric patients with B-cell precursor acute lymphoblastic leukaemia. Int J Lab Hematol. 2022; 44(4):769-76. [DOI: 10.1111/ijlh.13853] [PMID]
Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia. 2013; 27(7):1497-503. [DOI: 10.1038/leu.2013.44] [PMID]
Vrooman LM, Blonquist TM, Harris MH, Stevenson KE, Place AE, Hunt SK, et al. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv. 2018; 2(12):1449-58. [DOI: 10.1182/bloodadvances.2018016584] [PMID] [PMCID]
Singh M, Bhatia P, Trehan A, Varma N, Sachdeva MS, Bansal D, et al. High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction. Leuk Res. 2018; 66:79-84. [DOI: 10.1016/j.leukres.2018.01.012] [PMID]
Mullighan CG, Downing JR. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia. 2009; 23(7):1209-18. [DOI: 10.1038/leu.2009.18] [PMID]
Αmpatzidou Μ, Florentin L, Papadakis V, Paterakis G, Tzanoudaki M, Bouzarelou D, et al. Copy Number Alteration Profile Provides Additional Prognostic Value for Acute Lymphoblastic Leukemia Patients Treated on
BFM Protocols. Cancers. 2021 ;13(13):1-16. [DOI: 10.3390/cancers13133289] [PMID] [PMCID]
Lana T, de Lorenzo P, Bresolin S, Bronzini I, den Boer ML, Cavé H, et al. Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia. Leukemia. 2015; 29(10):2107-10. [DOI: 10.1038/leu.2015.78] [PMID]
van der Veer A, Zaliova M, Mottadelli F, de Lorenzo P, te Kronnie G, Harrison CJ, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood.
; 123(11):1691-8. [DOI: 10.1182/blood-2013-06-509794] [PMID]
Yeoh AEJ, Lu Y, Chin WHN, Chiew EKH, Lim EH, Li Z, et al. Intensifying treatment of childhood B-lymphoblastic leukemia with IKZF1 deletion reduces relapse and improves overall survival: Results of Malaysia-Singapore All 2010 study. J Clin Oncol. 2018; 36(26):2726–35. [DOI: 10.1200/JCO.2018.78.3050] [PMID]
Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome–positive acute lymphoblastic leukemia: Results of children’s oncology group trial AALL0622. J Clin Oncol. 2018; 36(22):2306–13. [DOI: 10.1200/JCO.2017.76.7228] [PMID] [PMCID]
Hinze L, Möricke A, Zimmermann M, Junk S, Cario G, Dagdan E, et al. Prognostic impact of IKZF1 deletions in association with vincristine–dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95. Leukemia. 2017; 31(8):1840-42. [DOI: 10.1038/leu.2017.154] [PMID] [PMCID]
Gupta SK, Bakhshi S, Chopra A, Kamal VK. Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection. Leuk Lymphoma. 2018; 59(8):1899-1904. [DOI: 10.1080/10428194.2017.1408087] [PMID]
Volejnikova J, Mejstrikova E, Dörge P, Meissner B, Zimmermannova O, Svojgr K, et al. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013; 60(3):420–7. [DOI: 10.1002/pbc.24299] [PMID]
Clappier E, Grardel N, Bakkus M, Rapion J, de Moerloose B, Kastner P, et al. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children’s Leukemia Group study 58951. Leukemia. 2015; 29(11):2154-61. [DOI: 10.1038/leu.2015.134] [PMID]
Olsson L, Ivanov Öfverholm I, Norén-Nyström U, Zachariadis V, Nordlund J, Sjögren H, et al. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013. Br J Haematol. 2015; 170(6):847-58. [DOI: 10.1111/bjh.13514] [PMID]
van der Sligte NE, G Scherpen FJ, ter Elst A, Guryev V, van Leeuwen FN, J M de Bont ES. Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Exp Hematol Oncol. 2015; 4:1-10. [DOI: 10.1186/s40164-015-0017-y] [PMID] [PMCID]
Ofverholm I, Tran AN, Heyman M, Zachariadis V, Nordenskjöld M, Nordgren A, et al. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols. Leukemia. 2013; 27(9):1936–9. [DOI: 10.1038/leu.2013.92] [PMID]
Gupta SK, Bakhshi S, Gupta R, Sharma P, Pushpam D, Sahoo RK, et al. IKZF1 Deletion Subtyping and Outcome Analysis in BCR-ABL1-Negative Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Institution Experience from North India. Clin Lymphoma Myeloma Leuk. 2021; 21(8):666-73. [DOI: 10.1016/j.clml.2021.03.007] [PMID]
Mitchell RJ, Kirkwood AA, Barretta E, Clifton-Hadley L, Lawrie E, Lee SW, et al. IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial. Blood Adv. 2021; 5(17):3322-32. [DOI: 10.1182/bloodadvances.2021004430] [PMID]
- Abstract Viewed: 394 times
- PDF Downloaded: 193 times
- MP3 Downloaded: 73 times